Navigation Links
Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update
Date:2/23/2012

evenues of $10.2 million in the year ended December 31, 2010. The Company reported a net loss of $52.0 million, or a loss of $0.57 per basic and diluted share, for the year ended December 31, 2011, compared to a net loss of $61.6 million, or a loss of $0.87 per basic and diluted share for the year ended December 31, 2010. The $9.6 million reduction in net loss in 2011 was due primarily to $7.2 million of non-recurring severance and restructuring expenses in 2010.

2012 Financial Guidance At December 31, 2011, Idenix's cash and cash equivalents totaled $118.3 million. The Company expects that its current cash, cash equivalents and the anticipated royalty payments associated with product sales of Tyzeka®/Sebivo® (telbivudine) will be sufficient to sustain its operations through at least the next twelve months from December 31, 2011. This guidance assumes no milestone payments, license fees, reimbursement for development programs and no financing activities.

ABOUT IDENIXIdenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical Company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of patients with hepatitis C infection. For further information about Idenix, please refer to www.idenix.com.

CONFERENCE CALL AND WEBCAST INFORMATIONIdenix will hold a conference call today at 4:30 p.m. ET. To access the call, please dial (877) 640-9809 (U.S./Canada) or (914) 495-8528 (International) and enter passcode 48802750. A slide presentation will accompany the conference call and can be accessed on the Investor section of the Idenix website at www.idenix.com. Please log on approximately 10 minutes prior to the start of the call to ensure adequate time for any downloads that may be necessary.

A replay of the conference call and webcast will be
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
2. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
3. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
4. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
5. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
6. Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
7. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
8. Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
9. Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2009 Financial Results
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Idenix Announces Data Presentations at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... ) has announced the addition of the ... report to their offering. Originally discovered ... as Yoshitomi Pharmaceutical Industries, Ltd) as an inflammatory ... by Senju Pharmaceutical Co., Ltd under the trade ...
(Date:8/28/2015)... , Aug. 28, 2015 ... has announced the addition of the "12th ... and Production" report to their offering. ... of Biopharmaceutical Manufacturing Capacity and Production is the ... manufacturing organizations, current and projected future capacity and ...
(Date:8/28/2015)...  Today, in final recognition of the Centers for ... 1-800 Contacts is sharing how to keep lens cases ... who do not properly care for their lens cases ... Most contact lens wearers understand the importance ... case is sometimes overlooked.  When proper steps to clean ...
Breaking Medicine Technology:Investigation Report on China's Pranoprofen Market, 2010-2019 212th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 21-800 Contacts Shares Tips on How to Clean Lens Cases 2
... 2011 Cumberland Pharmaceuticals Inc. ... on hospital acute care and gastroenterology markets, today announced that ... has been appointed Chief Financial Officer, effective Tuesday, October 18. ... since April of this year. Mr. Greene ...
... HILL, N.C., Oct. 12, 2011 Cempra Holdings, LLC, ... announced that it has filed a registration statement on ... (SEC) relating to its proposed initial public offering. ... and Company are serving as joint book-running managers for ...
Cached Medicine Technology:Cumberland Pharmaceuticals Appoints Rick S. Greene Chief Financial Officer 2Cumberland Pharmaceuticals Appoints Rick S. Greene Chief Financial Officer 3Cempra Holdings, LLC Files Registration Statement for Proposed Initial Public Offering 2
(Date:8/29/2015)... ... 2015 , ... On Saturday, September 19, 2015, Diane Blackburn-Zambetti, the Director of ... will present an educational program titled “Asbestos and Your Health.” , The two and ... open at 6:45pm) at Calvary United Methodist Church, 16 E Park Ave., Ambler, PA ...
(Date:8/29/2015)... ... August 29, 2015 , ... Targeted therapies, made possible ... lives of patients, according to a newly published report. Surviving Mesothelioma has more ... article. , The authors of the new paper focus on several types ...
(Date:8/29/2015)... York, NY (PRWEB) , ... August 29, 2015 , ... ... unofficial end of summer (which astronomically, officially ends on September 22nd this year). For ... summer-induced cyber security hangovers linger on which could prove far more costly than a ...
(Date:8/29/2015)... ... August 29, 2015 , ... Hamstring strain ... stretching, soft tissue manipulation. Platelet rich plasma injections also have mixed results. ... improve treatment outcomes. This localized treatment seems to address the symptoms and ...
(Date:8/28/2015)... ... , ... Rio Salado College joined nine educational institutions in Washington ... the EDUCAUSE - Next Generation Learning Challenges 2015 Breakthrough Models Incubator funded by the ... Models Incubator hosted by EDUCAUSE and NGLC, which is designed to bring leadership ...
Breaking Medicine News(10 mins):Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4
... , MONDAY, Jan. 10 (HealthDay News) -- The ... how to create a vaccine that can protect people against ... that people who were infected with the H1N1 virus and ... against a wide variety of flu strains. The virus ...
... By Amanda Gardner HealthDay Reporter , MONDAY, ... path through Rep. Gabrielle Giffords, brain on Saturday will likely ... point how extensive that damage might be. However, doctors ... Arizona congresswoman immediately after the shooting are already encouraged by ...
... is a highly subjective experience. We each have a pain ... A paper in the International Journal of Behavioural and ... pain in research. There are many chronic illnesses and ... because of the subjectivity in a patient,s reporting of their ...
... type of skin cancer. In this paper, Leif Ellisen and ... and p73 in SCC cells, and discovered a feedback loop ... SCC, they found that inhibiting one of these miRs decreased ... highlighting a new potential therapeutic target. , Squamous cell carcinoma ...
... researchers have found that a protein that plays an important ... due to additional mechanisms that cause it to promote atherosclerosis, ... the January issue of the journal Arteriosclerosis, Thrombosis and ... why some antioxidant therapies have not yielded more positive results. ...
... change during the 20th century in England and Wales in ... features in Alcohol and Alcoholism . While deaths ... the early part of the century, the pattern changed so ... lower social classes by the end of the century. ...
Cached Medicine News:Health News:People Who Recovered From H1N1 Offer Clues to Better Vaccine 2Health News:While Doctors Are Optimistic, Prognosis for Wounded Congresswoman Is Unclear 2Health News:While Doctors Are Optimistic, Prognosis for Wounded Congresswoman Is Unclear 3Health News:While Doctors Are Optimistic, Prognosis for Wounded Congresswoman Is Unclear 4Health News:Does it hurt? 2Health News:Protein thought to protect against oxidative stress also promotes clogging of arteries 2Health News:Social class and changes in mortality from liver cirrhosis over the 20th Century 2
QC 900 is an assayed quality control material for analyzers measuring hematocrit by electrical conductivity methodologies. It is available in two (2) levels for monitoring analyzer performance at var...
... is an assayed quality control ... measurements of total hemoglobin and ... It is available in three ... performance at varying points within ...
... is an assayed quality control material ... blood gas, electrolyte, metabolite, and CO-Oximeter ... control makes it the ideal choice ... is available in three (3) levels ...
Equinox is a truly unique approach to cosmetic enhancement contact lenses and is worn as a conventional wear lens....
Medicine Products: